• Latest
  • Sectors
    • Pharma
    • Biotech
    • MedTech
    • Regulation & Industry
  • In-House
  • Careers
  • Events
    • Events
    • Events News
    • Events Videos
    • Webinars
  • Insights
    • Whitepapers
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Copyright compliance in the life sciences industry
race-uphill-sand-dune
31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

In-house counsel
‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief
26 October 2026   Umicore’s Sean Alexander has seen the profession change considerably over three decades, but some of its biggest changes may still lie ahead. He tells LSIPR why AI is prompting difficult decisions, what he is no longer willing to pay external counsel for and why Europe is the place to watch.
Biotech
10x and Parse set to end sequencing feud after appeals court defeat
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
Pharma
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
22 October 2026   Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.


Editor's picks

WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026

Editor's picks

In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026

More features

Westlaw publisher scores landmark AI copyright win in US appeals court
Beyond the primary patent: How pharma can build competitive barriers
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
The UPC plugs another gap in its procedural rulebook
Brown Rudnick lands largest lateral IP team hire in firm history
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
‘Blatant imitation’: Indian court blocks copycat pharma branding
Kirkland & Ellis adds leading barrister in London

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin